Top 20 global biopharma companies report 2.3 per cent market cap growth in Q2 2023: GlobalData Read more
Blockbuster Enhertu may get tumor agnostic label, targeting any HER2-expressing cancer: GlobalData Read more
Enhertu improves both progression-free and overall survival in Destiny-Breast04 trial in patients with HER2-low metastatic breast cancer Read more
ENHERTU (fam-trastuzumab deruxtecan-nxki) gets US FDA nod for HER2-positive advanced gastric cancer Read more
Top 20 global pharma companies by MCap saw 10.2 per cent rise in MCap in Q2 2020: GlobalData Read more